BACKGROUND:

Bronchiolitis is often described to follow an expected clinical trajectory, with a peak in severity between days 3 and 5. This predicted trajectory may influence anticipatory guidance and clinical decision-making. We aimed to determine the association between day of illness at admission and outcomes, including hospital length of stay, receipt of positive-pressure ventilation, and total cough duration.

METHODS:

We compiled data from 2 multicenter prospective studies involving bronchiolitis hospitalizations in patients <2 years. Patients were excluded for complex conditions. We assessed total cough duration via weekly postdischarge phone calls. We used mixed-effects multivariable regression models to test associations between day of illness and outcomes, with adjustment for age, sex, insurance (government versus nongovernment), race, and ethnicity.

RESULTS:

The median (interquartile range) day of illness at admission for 746 patients was 4 (2–5) days. Day of illness at admission was not associated with length of stay (coefficient 0.01 days, 95% confidence interval [CI]: −0.05 to 0.08 days), positive-pressure ventilation (adjusted odds ratio: 1.0, 95% CI: 0.9 to 1.1), or total cough duration (coefficient 0.33 days, 95% CI: −0.01 to 0.67 days). Additionally, there was no significant difference in day of illness at discharge in readmitted versus nonreadmitted patients (5.9 vs 6.4 days, P = .54). The median cough duration postdischarge was 6 days, with 65 (14.3%) patients experiencing cough for 14+ days.

CONCLUSIONS:

We found no associations between day of illness at admission and outcomes in bronchiolitis hospitalizations. Practitioners should exercise caution when making clinical decisions or providing anticipatory guidance based on symptom duration.

What’s Known on This Subject:

Bronchiolitis has been described to follow an expected trajectory with a peak in illness severity between 3 and 5 days of illness. This anticipated trajectory may influence anticipatory guidance and clinical decision-making.

What This Study Adds:

Using data from 2 multicenter prospective studies, we demonstrate no association between day of illness and clinically important outcomes in bronchiolitis hospitalizations. Health care providers should be cautious about using day of illness to inform anticipatory guidance and decision-making.

Bronchiolitis is a common cause of hospitalization in infants and young children, currently accounting for ∼18% of overall pediatric hospitalizations.1  Management is mostly supportive,2  and discharge criteria vary among3  and within4  hospitals. Bronchiolitis is often described to follow an expected clinical trajectory, with a peak in severity of symptoms between days 3 and 5.57  This anticipated trajectory may influence anticipatory guidance and clinical decision-making. However, whether a predictable pattern based on day of illness applies to hospitalized patients with bronchiolitis has not been previously investigated. Using data from 2 multicenter, prospective studies,8,9  we aimed to determine the association between the day of illness at the time of hospital admission and subsequent hospital length of stay (LOS), receipt of positive-pressure ventilation (PPV), and total cough duration from the time of admission.

This investigation was a secondary analysis from 2 multicenter prospective studies in which follow-up strategies after bronchiolitis hospitalizations in generally healthy infants and children <2 years of age were examined. The first was an observational study of patients hospitalized at 5 hospitals (including 3 community hospitals) between December 2016 and March 2017.9  The second, the Bronchiolitis Follow-up Intervention Trial, was a randomized controlled trial (RCT) comparing follow-up strategies after hospital discharge, conducted at 4 hospitals (including 2 community hospitals) between January 2018 to April 2018 and November 2018 to April 2019.8 

Depicted in Table 1 is a breakdown of the contribution of patients from each study. For both studies, patients were considered for inclusion if they were hospitalized with an attending physician diagnosis of bronchiolitis and did not have complex medical conditions, including congenital heart disease, chronic lung disease, neuromuscular disease, or immunodeficiencies. Although the participating institutions encourage use of American Academy of Pediatrics guidelines2  for admission and discharge criteria, adherence to these guidelines was not mandatory for study inclusion. Patients were excluded for family refusal to participate and, in the RCT, if the primary team or primary care provider felt follow-up was indicated. Patients discharged from the hospital on supplemental oxygen were excluded from both original studies; however, because outcome data were collected on these patients in the RCT, we opted to include these patients for this analysis. Additionally, we collected LOS and PPV for all excluded patients in the RCT and included these patients in the analysis of LOS and PPV, although we did not collect information on PPV in the observational study. Total cough duration was available for patients in both studies who completed phone follow-up.

TABLE 1

Contribution of Patients From Each Study, Stratified by Predictor and Outcome Variables

StudyPredictor Variable: Duration of Symptoms at Presentation (n = 746)Outcome Variables
LOS (n = 746)Total Cough Duration (n = 456)PPV (n = 548)
Prospective cohort study9  All included patients (n = 198) All included patients (n = 198) All patients with complete phone follow-up data (n = 166) Not collected 
BeneFIT randomized trial9  All included patients and excluded patients (total n = 548) All included patients and excluded patients (total n = 548) All patients with complete phone follow-up data (n = 290)a All included and excluded patients (n = 548) 
StudyPredictor Variable: Duration of Symptoms at Presentation (n = 746)Outcome Variables
LOS (n = 746)Total Cough Duration (n = 456)PPV (n = 548)
Prospective cohort study9  All included patients (n = 198) All included patients (n = 198) All patients with complete phone follow-up data (n = 166) Not collected 
BeneFIT randomized trial9  All included patients and excluded patients (total n = 548) All included patients and excluded patients (total n = 548) All patients with complete phone follow-up data (n = 290)a All included and excluded patients (n = 548) 

BeneFIT, Bronchiolitis Follow-up Intervention Trial.

a

Includes 21 patients who were excluded from the RCT because they were discharged on supplemental oxygen but who nonetheless underwent phone follow-up.

The predictor variable was day of illness at the time of admission to the hospital. Investigators extracted this information from the admission history and physical and/or emergency department (ED) or urgent care notes. Day of illness was calculated as the total elapsed time, in days, between the date that the first symptom (eg, fever, runny nose, cough, difficulty feeding, difficulty breathing) related to bronchiolitis started and the date of admission. If notes described an interval with complete resolution of symptoms before admission, then the earlier period of symptoms was not included in the day of illness calculation.

The outcome variables included LOS, receipt of PPV, and total cough duration. We defined PPV as the need for endotracheal intubation or continuous or bilevel positive airway pressure, but we also examined a definition of PPV that included the use of high flow nasal cannula (HFNC). The study team extracted outcome variables from the medical record, with the exception of cough duration, which was obtained in both investigations via weekly phone follow-up calls conducted until the cough was reported by the caregiver to have stopped. We analyzed the association between day of illness and total cough duration from the time of admission but also report descriptive data on cough duration from the day of hospital discharge.

We conducted multivariable linear and Poisson regression, as appropriate, to analyze the association between the predictor and outcome variables, with adjustment for age, sex, insurance (government versus nongovernment), race, and ethnicity. We used mixed effects models to adjust for clustering by hospital. Comorbidities, including previous wheezing, eczema, and prematurity, were assessed during in-hospital interviews with caregivers on enrolled but not excluded patients, so these variables were added to the multivariable model as a sensitivity analysis. We did not include virology results as a covariate because most patients who underwent viral testing only had limited testing (for respiratory syncytial virus and influenza), but we did conduct a post hoc sensitivity analysis for respiratory syncytial virus–positive patients

Severity of illness might confound any association between day of illness and outcomes (ie, practitioners might factor day of illness into their decision to admit to the hospital). To assess for a potential association between day of illness and severity of illness, we adapted a scoring tool used by Freire et al10  to predict escalated care in bronchiolitis in the ED setting, and we applied this tool to a random sample of 100 patients. Please refer to the Supplemental Information for further explanation of our application of this tool. Because there was no association between severity of illness and day of illness (correlation coefficient: −0.01, P = .91), we opted not to include severity of illness as a covariate.

Because the sample size was predetermined for the 2 studies, we did not conduct an a priori sample size calculation; precision of our estimates is reflected in their confidence intervals (CIs).

Day of illness and LOS data were available for 746 patients. The median (interquartile range [IQR]) age was 6.4 (2.6–13) months, 423 (56.7%) patients were male, 318 (42.6%) had government insurance, 514 (68.9%) were identified as white race, and 229 (30.7%) were identified as Hispanic ethnicity (Table 2). The median (IQR) day of illness at admission was 4 (2–5) days, with 198 of 746 (26.5%) patients presenting before the third day of illness and with 121 of 746 (16.2%) presenting after the fifth day (Fig 1). The median (IQR) LOS was 2 (1–3) days, a total of 218 of 746 (29.2%) patients were hospitalized in the ICU, and for the 548 patients for whom the degree of respiratory support was documented, 88 (16.1%) received PPV and 233 (42.5%) received PPV or HFNC.

TABLE 2

Characteristics of Enrolled Patients

Patient CharacteristicOverall Sample (n = 746)
Age, mo, mean (IQR) 6.4 (2.6–13) 
Male sex, n (%) 423 (56.7) 
Government insurance, n (%) 318 (42.6) 
Race, n (%)  
 White 574 (76.9) 
 Native Hawaiian or Pacific Islander 62 (8.3) 
 Asian American 59 (7.9) 
 Black or African American 15 (2) 
 American Indian or Alaskan Native 5 (0.7) 
 Other 31 (4.2) 
Hispanic, n (%) 229 (30.7) 
Duration of symptoms on presentation in d, median (IQR) 4 (2–5) 
Underwent viral testing,an (%) 591 (79.2) 
Positive viral test among those tested, n (%) 517 (87.4) 
Positive respiratory syncytial virus among those with viral testing, n (%) 410 (69.4) 
Patient CharacteristicOverall Sample (n = 746)
Age, mo, mean (IQR) 6.4 (2.6–13) 
Male sex, n (%) 423 (56.7) 
Government insurance, n (%) 318 (42.6) 
Race, n (%)  
 White 574 (76.9) 
 Native Hawaiian or Pacific Islander 62 (8.3) 
 Asian American 59 (7.9) 
 Black or African American 15 (2) 
 American Indian or Alaskan Native 5 (0.7) 
 Other 31 (4.2) 
Hispanic, n (%) 229 (30.7) 
Duration of symptoms on presentation in d, median (IQR) 4 (2–5) 
Underwent viral testing,an (%) 591 (79.2) 
Positive viral test among those tested, n (%) 517 (87.4) 
Positive respiratory syncytial virus among those with viral testing, n (%) 410 (69.4) 
a

Many patients only underwent rapid testing for respiratory syncytial virus and influenza.

FIGURE 1

The distribution of day of illness on hospital admission.

FIGURE 1

The distribution of day of illness on hospital admission.

Close modal

The unadjusted association between day of illness at admission and LOS is depicted in Fig 2, with day of illness categorized into 5 groups. On multivariable analysis, day of illness at admission was not associated with LOS (coefficient for each additional day of illness on presentation 0.01 days, 95% CI: −0.05 to 0.08 days, P = .68), PPV (incidence rate ratio [IRR] for each additional day of illness on presentation 1.0, 95% CI: 0.9 to 1.1, P = .94), or total cough duration (coefficient 0.33 days, 95% CI: −0.01 to 0.67 days, P = .06) (Table 3). When HFNC is included in the definition of PPV, the association with day of illness is also not statistically significant (IRR 0.95, 95% CI: 0.9 to 1, P = .13). The addition to the model of previous wheezing, eczema, and prematurity for the 563 patients on whom those variables were available had minimal impact on effect sizes and did not impact statistical significance for any of the 3 outcomes (Table 3). A post hoc analysis of patients who were RSV positive similarly did not impact effect sizes or statistical significance.

FIGURE 2

The association between day of illness at presentation (in categories) and hospital LOS (error bars represent 95% CIs).

FIGURE 2

The association between day of illness at presentation (in categories) and hospital LOS (error bars represent 95% CIs).

Close modal
TABLE 3

Unadjusted and Adjusted Associations Between Day of Illness at Admission and Outcomes

OutcomeDay of Illness (Unadjusted)PDay of Illness (Main Adjusted Model)aPDay of Illness (Additional Adjusted Model)bP
LOS, d, coefficient (95% CI) 0.02 (−0.04 to 0.08) .46 0.01 (−0.05 to 0.08) .68 0.01 (−0.07 to 0.09) .78 
PPV, IRR (95% CI) 1.0 (0.9 to 1.1) .98 1.0 (0.9 to 1.1) .94 0.9 (0.8 to 1.1) .39 
PPV including HFNC, OR (95% CI) 1.0 (0.9 to 1.0) .17 1.0 (0.9 to 1.0) .13 0.9 (0.9 to 1.0) .20 
Total cough duration, d, coefficient (95% CI) 0.32 (−0.01 to 0.66) .06 0.33 (−0.01 to 0.67) .06 0.31 (−0.03 to 0.65) .07 
OutcomeDay of Illness (Unadjusted)PDay of Illness (Main Adjusted Model)aPDay of Illness (Additional Adjusted Model)bP
LOS, d, coefficient (95% CI) 0.02 (−0.04 to 0.08) .46 0.01 (−0.05 to 0.08) .68 0.01 (−0.07 to 0.09) .78 
PPV, IRR (95% CI) 1.0 (0.9 to 1.1) .98 1.0 (0.9 to 1.1) .94 0.9 (0.8 to 1.1) .39 
PPV including HFNC, OR (95% CI) 1.0 (0.9 to 1.0) .17 1.0 (0.9 to 1.0) .13 0.9 (0.9 to 1.0) .20 
Total cough duration, d, coefficient (95% CI) 0.32 (−0.01 to 0.66) .06 0.33 (−0.01 to 0.67) .06 0.31 (−0.03 to 0.65) .07 

OR, odds ratio.

a

Adjusted for age, sex, insurance (public versus private), race, and ethnicity.

b

Additional adjustment for previous wheezing, eczema, and prematurity for the 563 patients for whom these data were available.

Information on hospital readmission was available for 424 patients. A total of 16 (3.8%) patients were readmitted, and there was no significant difference in the day of illness at discharge in readmitted versus nonreadmitted patients (5.9 vs 6.4 days, P = .83 with adjustment for age, sex, insurance, race, and ethnicity). Patients discharged early in the course of their illness (third day of illness or earlier) had a similar readmission risk to those discharged on or beyond their fourth day of illness (3.4% vs 3.8%, P = .87). The median (IQR) cough duration after hospital discharge was 6 (3–10) days, with 65 (14.3%) patients having cough for 2 weeks or more.

In this secondary analysis of 2 prospective, multicenter studies involving hospitalized bronchiolitis patients, we observed no association between day of illness at the time of admission and subsequent outcomes, including LOS, receipt of PPV, or total duration of cough. Our findings should help inform the anticipatory guidance provided to families during bronchiolitis hospitalizations and might discourage practitioners from using day of illness to influence clinical decision-making.

A commonly used educational resource for clinical guidance states that bronchiolitis “begins with upper respiratory tract symptoms, followed by lower respiratory tract signs and symptoms on days 2 to 3, which peak on days 3 to 5 and then gradually resolve.”5  Authors of 1 bronchiolitis review article describe day of illness as “an important variable in providing anticipatory guidance for outpatient management.”6  We are not aware of any data describing how frequently practitioners factor in the day of illness into their clinical decision-making. However, in our review of admission notes for these 2 studies, we noted that most assessments and plans included mention of day of illness, inferring that this variable is often part of the patient’s narrative.

Although researchers of multiple studies have investigated total symptom duration in infants and young children with bronchiolitis, we were unable to find reliable evidence supporting a peak in severity between 3 and 5 days in either the inpatient or outpatient setting. Swingler et al11  demonstrated that the median duration of illness in outpatients evaluated for bronchiolitis was 12 days, with 18% still reporting symptoms after 21 days, whereas 25% of patients with bronchiolitis seen in an ED were noted to have persistent symptoms after 21 days.12  However, researchers of neither study evaluated the timing of peak symptoms or evolution of severity of illness. Leidy et al13  and Robbins et al14  described prolonged recoveries after bronchiolitis hospitalizations but similarly did not describe the time course of disease severity. Authors of some studies of bronchiolitis therapies have reported days of symptoms before enrollment and daily illness severity after administration of the study drug15  but do not aggregate these time points at the patient level, which makes deciphering the exact peak in severity challenging. Researchers of human challenge studies involving young, healthy adults have demonstrated that symptoms tend to correlate with viral load, tend to start within 1 to 2 days of inoculation, and peak ∼5 to 8 days after inoculation.16,17 

Therefore, the notion that disease severity tends to peak on days 3 to 5 may be derived from adult experimental models but is not necessarily supported or contradicted by evidence from children. Although diseases that are acute and self-limited by definition will exhibit a peak in severity sometime between symptom onset and symptom resolution, with our findings, we suggest that severe bronchiolitis (ie, that which requires hospitalization) may be a heterogeneous disease with a variable and unpredictable trajectory. Recent data describing viral coinfections in ∼30% of hospitalized patients may be used to explain some of this heterogeneity,18  although associations between being infected with >1 virus and hospital LOS were not particularly strong in that study.

Rather than using the day of illness to anchor clinical management and anticipatory guidance, day-to-day progress may be a more reliable predictor of the disease trajectory. In a prospective multicenter study of 1916 patients hospitalized with bronchiolitis, Mansbach et al19  demonstrated that deterioration after a period of clinical improvement was rare, occurring in only 4% of patients. The authors also noted that patients with ≥1 day of breathing difficulty at presentation had no difference when compared with patients with <1 day of breathing difficulty in the likelihood of subsequent clinical worsening after having initial improvement, which supports our finding that day of illness has poor predictive value.

However, in a related study from the same patient cohort, the authors noted that patients with <1 day breathing difficulty at the time of presentation had higher odds of needing mechanical ventilation (odds ratio of 1.6, 95% CI: 1.2 to 2.1), a finding that motivated our analysis of PPV.18  The authors of that study drew comparisons between their findings and rapidly progressive influenza, where deaths have been reported to occur early in the course of the illness.20,21  However, their findings contrast with ours, even when HFNC is added to the definition of PPV. Although this contrast may be explained by differences in study design and sample size, it suggests that associations between the timing of the disease course and the need for escalation of respiratory support remain unclear.

One potential explanation for the lack of association between day of illness and outcomes in our study is that severity of illness at presentation may confound this association. For example, practitioners may be more likely to hospitalize an infant who is early in the course of their illness because of fear that they may worsen. This phenomenon would bias toward the null hypothesis because patients earlier in the course would therefore be less ill and expected to fare better, thereby neutralizing any association with day of illness. Using the score developed by Freire et al,10  we found that severity of illness in a random sample of 100 patients was not associated with day of illness, which gave us some reassurance that severity of illness was not an important confounder in our study.

We did not attempt to adjust for severity of illness at discharge. Day of illness might also impact the decision to discharge, but in this case, any confounding due to severity of illness would bias away from the null hypothesis in that patients earlier in the course of illness would be hospitalized longer although they are less ill. Therefore, this potential bias should not have influenced our main findings.

In our study, we provide descriptive data on duration of cough after discharge. Our finding that cough persists for about a week in most patients but ≥2 weeks in 14.3% (1 in 7) of patients may be useful as anticipatory guidance at discharge. An understanding that symptoms are often persistent may prevent unneeded subsequent visits.

Our study has several limitations. First, because of differences in protocols for the original studies, the data fields differed, which affected the sample sizes for some outcomes (eg, we did not record PPV data in the observational study). Second, we did not have precise criteria for determination of onset of illness and relied on documentation from admission notes. Although similar approaches have been used in multiple other bronchiolitis studies to determine illness duration on admission,15,2224  this measure is subject to caregiver recall and may not reflect the true trajectory of the disease. Third, total cough duration was assessed by weekly phone calls. Although parents were instructed on enrollment that they would be asked about duration of symptoms, symptom diaries were not required. Fourth, we did not have comprehensive virology data because most patients who underwent viral testing were only tested for RSV and influenza. In future investigations, researchers should further evaluate the influence of viral etiology on disease trajectory. Finally, for PPV, we did not record the date of initiation, which might have provided additional insight into the timing of peak severity of illness.

Caregiver-reported day of illness at presentation does not appear to be associated with hospital LOS, receipt of PPV, or total cough duration in bronchiolitis hospitalizations. Severe bronchiolitis is a heterogeneous condition with an unpredictable clinical course. Practitioners should exercise caution when making clinical decisions or providing anticipatory guidance on the basis of symptom duration.

Dr Schroeder conceptualized and designed the study, coordinated and supervised data collection, designed the data collection instruments, collected data, and drafted the initial manuscript; Drs Destino and Coon conceptualized and designed the study, coordinated and supervised data collection, designed the data collection instruments, and collected data; Drs Brooks, Ip, and Vukin collected data; Mr Stoddard provided statistical consultation; and all authors reviewed and revised the manuscript and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

FUNDING: Funding for the original 2 studies on which this investigation was based was provided by a joint program between Intermountain Healthcare and Stanford School of Medicine, by the Department of Pediatrics at Stanford University School of Medicine, and by the Division of Pediatric Inpatient Medicine at Primary Children’s Hospital. The funders were not involved in the design of the trial, the analysis of the data, the writing of the article, or the decision to publish.

CI

confidence interval

ED

emergency department

HFNC

high flow nasal cannula

IQR

interquartile range

IRR

incidence rate ratio

LOS

length of stay

PPV

positive-pressure ventilation

RCT

randomized controlled trial

1
Fujiogi
M
,
Goto
T
,
Yasunaga
H
, et al
.
Trends in bronchiolitis hospitalizations in the United States: 2000–2016
.
Pediatrics
.
2019
;
144
(
6
):
e20192614
2
Ralston
SL
,
Lieberthal
AS
,
Meissner
HC
, et al.;
American Academy of Pediatrics
.
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis
.
Pediatrics
.
2014
;
134
(
5
). Available at: www.pediatrics.org/cgi/content/full/134/5/e1474
3
Ralston
SL
,
Garber
MD
,
Rice-Conboy
E
, et al.;
Value in Inpatient Pediatrics Network Quality Collaborative for Improving Hospital Compliance with AAP Bronchiolitis Guideline (BQIP)
.
A multicenter collaborative to reduce unnecessary care in inpatient bronchiolitis
.
Pediatrics
.
2016
;
137
(
1
)
4
Garcia-Mauriño
C
,
Moore-Clingenpeel
M
,
Wallihan
R
, et al
.
Discharge criteria for bronchiolitis: an unmet need
.
Pediatr Infect Dis J
.
2018
;
37
(
6
):
514
519
5.
Piedra
PA
,
Stark
AR
.
Bronchiolitis in infants and children: clinical features and diagnosis.
UpToDate.
2019
. Available at: https://www.uptodate.com/contents/bronchiolitis-in-infants-and-children-clinical-features-and-diagnosis. Accessed February 1, 2020
6
Wagner
T
.
Bronchiolitis
.
Pediatr Rev
.
2009
;
30
(
10
):
386
395
7
Silver
AH
,
Nazif
JM
.
Bronchiolitis
.
Pediatr Rev
.
2019
;
40
(
11
):
568
576
8
Coon
ER
,
Destino
LA
,
Greene
TH
,
Vukin
E
,
Stoddard
G
,
Schroeder
AR
.
Comparison of as-needed and scheduled posthospitalization follow-up for children hospitalized for bronchiolitis: The Bronchiolitis Follow-up Intervention Trial (BeneFIT) randomized clinical trial [published online ahead of print July 6, 2020]
.
JAMA Pediatr
.
2020
9
Schroeder
AR
,
Destino
LA
,
Brooks
R
,
Wang
CJ
,
Coon
ER
.
Outcomes of follow-up visits after bronchiolitis hospitalizations
.
JAMA Pediatr
.
2018
;
172
(
3
):
296
297
10
Freire
G
,
Kuppermann
N
,
Zemek
R
, et al.;
Pediatric Emergency Research Networks (PERN)
.
Predicting escalated care in infants with bronchiolitis
.
Pediatrics
.
2018
;
142
(
3
):
e20174253
11
Swingler
GH
,
Hussey
GD
,
Zwarenstein
M
.
Duration of illness in ambulatory children diagnosed with bronchiolitis
.
Arch Pediatr Adolesc Med
.
2000
;
154
(
10
):
997
1000
12
Petruzella
FD
,
Gorelick
MH
.
Duration of illness in infants with bronchiolitis evaluated in the emergency department
.
Pediatrics
.
2010
;
126
(
2
):
285
290
13
Leidy
NK
,
Margolis
MK
,
Marcin
JP
, et al
.
The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery
.
Pediatrics
.
2005
;
115
(
6
):
1536
1546
14
Robbins
JM
,
Kotagal
UR
,
Kini
NM
,
Mason
WH
,
Parker
JG
,
Kirschbaum
MS
.
At-home recovery following hospitalization for bronchiolitis
.
Ambul Pediatr
.
2006
;
6
(
1
):
8
14
15
Hall
CB
,
McBride
JT
,
Walsh
EE
, et al
.
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study
.
N Engl J Med
.
1983
;
308
(
24
):
1443
1447
16
Lee
FE
,
Walsh
EE
,
Falsey
AR
,
Betts
RF
,
Treanor
JJ
.
Experimental infection of humans with A2 respiratory syncytial virus
.
Antiviral Res
.
2004
;
63
(
3
):
191
196
17
DeVincenzo
JP
,
Wilkinson
T
,
Vaishnaw
A
, et al
.
Viral load drives disease in humans experimentally infected with respiratory syncytial virus
.
Am J Respir Crit Care Med
.
2010
;
182
(
10
):
1305
1314
18
Mansbach
JM
,
Piedra
PA
,
Stevenson
MD
, et al.;
MARC-30 Investigators
.
Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation
.
Pediatrics
.
2012
;
130
(
3
). Available at: www.pediatrics.org/cgi/content/full/130/3/e492
19
Mansbach
JM
,
Clark
S
,
Piedra
PA
, et al.;
MARC-30 Investigators
.
Hospital course and discharge criteria for children hospitalized with bronchiolitis
.
J Hosp Med
.
2015
;
10
(
4
):
205
211
20
Bhat
N
,
Wright
JG
,
Broder
KR
, et al.;
Influenza Special Investigations Team
.
Influenza-associated deaths among children in the United States, 2003–2004
.
N Engl J Med
.
2005
;
353
(
24
):
2559
2567
21
Libster
R
,
Bugna
J
,
Coviello
S
, et al
.
Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina
.
N Engl J Med
.
2010
;
362
(
1
):
45
55
22
Plint
AC
,
Johnson
DW
,
Patel
H
, et al.;
Pediatric Emergency Research Canada (PERC)
.
Epinephrine and dexamethasone in children with bronchiolitis
.
N Engl J Med
.
2009
;
360
(
20
):
2079
2089
23
Rodriguez
WJ
,
Gruber
WC
,
Groothuis
JR
, et al
.
Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
.
Pediatrics
.
1997
;
100
(
6
):
937
942
24
Skjerven
HO
,
Hunderi
JO
,
Brügmann-Pieper
SK
, et al
.
Racemic adrenaline and inhalation strategies in acute bronchiolitis
.
N Engl J Med
.
2013
;
368
(
24
):
2286
2293

Competing Interests

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

Supplementary data